Figure 8

SRVF administration suppresses tumor growth in vivo. Balb/c nude mice were subcutaneously injected with HT1080 cells. After 7 days, mice were administered an equal volume of saline (control) or 50 or 100 mg/kg SRVF daily for 14 days (n = 6 per group). (A) Tumor volume was calculated by measuring the tumor size on two axes of the tumors according to the following formula: tumor volume = (length) × (width)² × 0.52. Statistical significance was evaluated with Student’s t-test. *p < 0.05, **p < 0.01 vs. No SRVF. (B,C) At the time of sacrifice (day 21), tumors were excised, weighed, and photographed. Bars represent the mean value of each group (n = 6), and statistical significance was determined using Student’s t-test. Statistical significance was evaluated with Student’s t-test. **p < 0.01 vs. No SRVF. (D) Cryosections of HT1080 xenograft tumors obtained from saline-treated control group and SRVF-treated group were immunostained for Ki67 expression. (E) Each group of normal mice (n = 3) was administered saline or, 50 or 100 mg/kg SRVF for 21 days. After sacrifice, body and organ weight were measured and are expressed as the mean ± SD.